Financial Data and Key Metrics Changes - Total pro forma worldwide revenue for Q4 FY 2024 was $71.1 million, representing a growth of approximately 2% year-over-year [7] - For the full fiscal year, revenue was $270.7 million, reflecting a growth of 5.3% [9] - Adjusted EBITDA for Q4 FY 2024 was $1.5 million, compared to $1.3 million in Q4 FY 2023 [35] - The company narrowed its adjusted loss per share to $0.05 in Q4 FY 2024 from $0.11 in the prior year [34] Business Line Data and Key Metrics Changes - Med Tech segment revenue grew 11% year-over-year in Q4 FY 2024, driven by Auryon and NanoKnife [7][27] - Med Device segment revenue declined approximately 4% in Q4 FY 2024, primarily due to reorganization impacts [8][31] - Auryon platform contributed $13 million in revenue during Q4, growing 12% compared to last year [28] - NanoKnife disposable revenue increased 18% year-over-year in Q4, with total NanoKnife sales up 30.5% for the full year [30] Market Data and Key Metrics Changes - Med Tech platforms comprised 41% of total revenue in Q4 FY 2024, up from 38% a year ago [27] - The total addressable market (TAM) for Med Tech has expanded from approximately $3 billion to roughly $10 billion since 2021 [10] Company Strategy and Development Direction - The company is focused on pursuing larger and faster-growing Med Tech markets, driving portfolio optimization, and deploying focused resource development [10][16] - The strategic transformation initiated in July 2021 has led to nearly doubling the revenue contribution from the Med Tech portfolio [18] - The transition to a fully outsourced manufacturing model is expected to generate approximately $15 million in annualized savings by fiscal 2027 [21] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the Med Tech business, particularly with upcoming product launches and FDA approvals [41] - The company anticipates revenue for FY 2025 to be in the range of $282 million to $288 million, representing growth of 4.2% to 6.4% [38] - Management highlighted the importance of maintaining a strong balance sheet to support growth initiatives [36] Other Important Information - The company achieved a settlement in a long-standing IP litigation dispute, providing clarity and enabling a focus on innovation [22] - Nearly all products have received updated EU MDR approval, positioning the company well for international expansion [23] Q&A Session Summary Question: Guidance for next year, especially regarding Med Tech growth - Management indicated that some growth from the prostate indication is included in the guidance, but does not expect a significant spike post-indication [45][46] Question: Stability of AngioVac and efforts to maintain it - Management noted that AngioVac's stability is due to its unique design and targeted sales force training [53] Question: Reimbursement efforts for NanoKnife - Management is actively working on reimbursement pathways and expects to achieve significant value from NanoKnife through these efforts [58][60] Question: Differences in commercial strategies between the U.S. and Europe for AlphaVac - Management stated that while the fundamentals are the same, the U.S. market has progressed faster, and extensive training is being provided to the European team [64]

AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 16, 2024 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunitie ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 70%. A quarter ago, it was expected that this medical device maker would post a loss of $0.14 per share when it actually produced a loss of $0.16, delivering a surprise of -14.29%.Over the last four quarters, the company ...

Exhibit 99.1 /namics PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patient ...

AngioDynamics, Inc. (ANGO) recently announced the European CE Mark approval for its AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and the treatment of pulmonary embolism (PE).The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is enhanced by the CE Mark approval, which is likely a significant step forward in improving patient care and safety for endovascular therapies in the EU, a mar ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioD ...

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 16 cents for third-quarter fiscal 2024, wider than the year-ago loss of 3 cents per share and the Zacks Consensus Estimate of a loss of 14 cents per share.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC and Midline product portfolios and the discontinued Uniblate, Starburst and Syntrax products), adjusted loss per share in third-quarter fiscal 2024 was also 16 cents, wider than the adjusted loss per share ...

Company Developments - AngioDynamics, Inc. (ANGO) received FDA 510(k) clearance for its AlphaVac F1885 System, which is now indicated for the treatment of pulmonary embolism (PE) [1] - The AlphaVac F1885 System is designed for non-surgical excision of thrombi or emboli from the venous vasculature, enhancing therapy options for PE patients [1][4] - The APEX-AV Study, which enrolled 122 patients, demonstrated the system's efficacy in reducing clot burden and improving right ventricular function [5][6] - AngioDynamics has settled patent litigation with Becton, Dickinson and Company, which is expected to reduce legal expenses and distractions for the company [9] Financial Performance - Over the past six months, ANGO's shares have decreased by 10.5%, while the industry has increased by 20.6% and the S&P 500 has gained 19.8% [2] Market Insights - The global pulmonary embolism market was valued at $1.65 billion in 2022 and is projected to exceed $3.12 billion by 2030, growing at a rate of 8.3% [8] - The growth of the pulmonary embolism market is driven by increasing cancer prevalence and rising healthcare expenditures [8]

Financial Data and Key Metrics Changes - The company reported revenue of $66 million for Q3 FY24, representing an 8% year-over-year growth, with med tech segment growth of nearly 13% and med device segment growth of 5% [10][20] - Adjusted net loss for Q3 FY24 was $6.5 million, or adjusted loss per share of $0.16, compared to an adjusted net loss of $5.4 million or adjusted loss per share of $0.14 in the same quarter last year [26] - GAAP net loss for Q3 FY24 was $190.4 million, including a goodwill impairment charge of $159.5 million [27] Business Line Data and Key Metrics Changes - Med tech revenue was $25.7 million, a 12.6% year-over-year increase, while med device revenue was $40.3 million, growing 5.2% compared to Q3 FY23 [20] - Auryon platform contributed $11.8 million in revenue during Q3, growing 14.7% year-over-year [21] - NanoKnife disposable revenue increased 19.8% year-over-year, with capital sales growing 230.9% [22] Market Data and Key Metrics Changes - International business grew approximately 21% year-over-year, with med tech growing 53% and med device growing 7% [16] - The company expects to initiate a limited launch of AlphaVac for pulmonary embolism treatment by the end of Q4 FY24, with a full launch scheduled for Q1 FY25 [12][13] Company Strategy and Development Direction - The company is focused on optimizing its portfolio, having divested its PICC and midline product portfolios for up to $45 million, with $30 million received in Q3 [17] - The transition to a fully outsourced manufacturing model is underway, expected to generate approximately $15 million in annualized savings starting in FY26 [18][24] - The company aims to drive growth from key med tech platforms while expanding margins and moving towards profitability [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy, highlighting the FDA clearance for AlphaVac as a significant milestone [12] - The company anticipates FY24 revenue in the range of $270 million to $275 million, reflecting the impact of recent divestitures [32] - Management noted that there are no significant market changes affecting guidance, maintaining a consistent outlook despite operational transitions [42] Other Important Information - The company has zero debt compared to $50 million a year ago, significantly strengthening its balance sheet [28][30] - A settlement agreement with BD Bard was reached, resolving over a decade of IP litigation, providing clarity and allowing the company to focus on growth [31] Q&A Session Summary Question: When will data from the APEX trial be available? - Management indicated that data will be released at upcoming trade shows and through publications from principal investigators [36] Question: What are the rollout plans for AlphaVac in PE? - The company has prepared its sales force and will conduct a limited market release followed by a larger launch [48] Question: Will there be any changes in guidance due to recent divestitures? - Management confirmed that guidance remains consistent, reflecting the divestiture's impact without significant market changes [42] Question: What is the pricing strategy for AlphaVac? - The expected price for AlphaVac is around $9,000 [60] Question: How is the NanoKnife performing and when will PRESERVE data be available? - The NanoKnife is seeing strong growth, particularly in prostate treatments, with data from the PRESERVE study expected to be published following the 12-month follow-up [62]

Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture Fiscal Year 2024 Third Quarter Highlights • Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 o Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support ...